Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial
Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial. // The Lancet Neurology. – URL: https://www.sciencedirect.com/science/article/pii/S1474442226003601?dgcid=rss_sd_all
Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial. The Lancet Neurology. https://www.sciencedirect.com/science/article/pii/S1474442226003601?dgcid=rss_sd_all
“Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial.” The Lancet Neurology.
@article{article108851,
title = {Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial},
journal = {The Lancet Neurology},
url = {https://www.sciencedirect.com/science/article/pii/S1474442226003601?dgcid=rss_sd_all}
}